The new syndicated study will combine real world evidence on the treatment of HS patients with treating doctors’ perceptions, providing a comprehensive understanding of the HS landscape in the EU5. Subscribers to the Monitor will be able to examine and size the HS market in each country (including the biologic market), understand HS patient journeys, gauge doctors’ perceptions of products used to treat HS, assess their treatment approaches, and much more.
The HS Therapy Monitor extends Ipsos’ Autoimmune RWE portfolio, which also includes Rheumatoid Arthritis, Spondyloarthropathies, Crohn’s Disease, Ulcerative Colitis, Psoriasis and Multiple Sclerosis diseases.
Ipsos Healthcare Launches Syndicated Pan-Cancer Testing Monitor in Australia
Ipsos Healthcare has announced the expansion of its syndicated Pan-Cancer Testing Monitor (PCTM) to the Australian market. The PCTM, which has been running in the US since 2016, measures and tracks the usage of pan-cancer tests, which are designed to test for a wide range of cancer types to help doctors make more informed treatment decisions.